Biomark Diagnostics Logo
CA09073K1084

Biomark Diagnostics

Ins Portfolio
60% Chancen, 40% Gelassenheit. Aktien und Anleihen in einem LifeStrategy ETF. Jetzt entdecken
Anzeige

Kurse werden geladen...

 Anzeige

Prognose

Für dieses Unternehmen liegen uns keine Analysten-Daten vor.

Scoring-Modelle

Für dieses Unternehmen liegen uns bisher keine Scoring-Modelle vor.

News

  • Foto von BioMark Diagnostics Announces Landmark Publication Validating High Specificity and Accuracy of Its Early-Stage Lung Cancer Test

    BioMark Diagnostics Announces Landmark Publication Validating High Specificity and Accuracy of Its Early-Stage Lung Cancer Test

    Study Published in a special issue of International Journal of Molecular Sciences Confirms Test's Ability to Distinguish Early Lung Cancer from Other Non-Cancerous Lung Diseases Vancouver, British Columbia--(Newsfile Corp. - May 12, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark"), a leading developer of liquid biopsy tests for early cancer detection, today announced the publication of a pivotal study as part of the special issue Molecular Pathogenesis and Diagnostics of Lung Diseases of the International Journal of Molecular Sciences. The research, titled "Clinical Validation of Plasma Metabolite Markers for Early Lung Cancer Detection", provides significant external validation for BioMark's metabolomics and machine learning powered technology, particularly highlighting its high specificity and accuracy in detecting early-stage non-small cell lung cancer (NSCLC) and differentiating it from other non-cancerous lung conditions.» Mehr auf newsfilecorp.com

  • Foto von BioMark Diagnostics Announces Uplisting to OTCQB Venture Market

    BioMark Diagnostics Announces Uplisting to OTCQB Venture Market

    Milestone strengthens transparency and credibility as the Company advances commercialization of its metabolomics technology platform Vancouver, British Columbia--(Newsfile Corp. - May 8, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (OTCQB: BMKDF) (FSE: 20B) ("BioMark" or the "Company"), a leading developer of liquid biopsy tests for early cancer detection, is pleased to announce that its common shares have been officially approved for uplisting from the OTC Pink Open Market to the OTCQB Venture Market under the symbol "BMKDF" on May 8th, 2025. Additionally, the Company's common shares will maintain its eligibility for settlement through the Depository Trust Company ("DTC"), a subsidiary of the Depository Trust & Clearing Corp., which facilitates the electronic clearing and settlement of publicly traded companies in the United States.» Mehr auf newsfilecorp.com

  • Foto von BioMark Announces the Final Closing of Oversubscribed Private Placement

    BioMark Announces the Final Closing of Oversubscribed Private Placement

    Vancouver, British Columbia--(Newsfile Corp. - March 31, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark"), a leading developer of liquid biopsy tests for early cancer detection, today announced the successful closing of its previously announced oversubscribed non-brokered private placement. The closing of the second and final tranche builds upon the momentum of the previously announced first tranche on March 26, 2025, culminating in a significantly successful financing round.» Mehr auf newsfilecorp.com

Unternehmenszahlen

Im letzten Quartal hatte Biomark Diagnostics einen Umsatz von +25,82k und ein Nettoeinkommen von 224,18k
(EUR)Dez. 2024
YOY
Umsatz+25,82k8,95%
Bruttoeinkommen+25,82k8,95%
Nettoeinkommen224,18k19,27%
EBITDA175,18k10,72%

Fundamentaldaten

MetrikWert
Marktkapitalisierung
+15,44 Mio
Anzahl Aktien
90,89 Mio
52 Wochen-Hoch/Tief
+0,20 - +0,10
DividendenNein
Beta
-0,4
KGV (PE Ratio)
12,13
KGWV (PEG Ratio)
2,97
KBV (PB Ratio)
20,96
KUV (PS Ratio)
+158,29

Unternehmensprofil

BioMark Diagnostics Inc. ist ein auf die Onkologie spezialisiertes Unternehmen, das Lösungen für die Krebsdiagnose zur Erkennung, Überwachung und Bewertung der Frühbehandlung entwickelt. Es hat eine Forschungskooperation mit der Icahn School of Medicine für klinische Studien im Zusammenhang mit der Frühdiagnose von Lungenkrebs vereinbart. Das Unternehmen wurde 2014 gegründet und hat seinen Hauptsitz in Richmond, Kanada. BioMark Diagnostics Inc. ist eine Tochtergesellschaft von Biomark Technologies Inc.

Name
Biomark Diagnostics
CEO
Rashid Ahmed Maula Bux B.Sc., MBA
SitzRichmond, bc
Kanada
Website
Börsengang
Mitarbeiter0

Ticker Symbole

BörseSymbol
Cnq
BUX.CN
Pnk
BMKDF
Frankfurt
20B.F
🍪

Parqet nutzt Cookies.Erfahre Mehr